Our top pick for
Immutep Limited is a biotechnology business based in the US. Immutep shares (IMMP) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||$0.91 - $3.95|
|50-day moving average||$3.14|
|200-day moving average||$2.76|
|Wall St. target price||$7.01|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$6.4 million|
|Gross profit TTM||$-6,656,699|
|Return on assets TTM||-20%|
|Return on equity TTM||-61.68%|
|Market capitalisation||$222.6 million|
TTM: trailing 12 months
There are currently 118,758 Immutep shares held short by investors – that's known as Immutep's "short interest". This figure is 64.7% down from 336,236 last month.
There are a few different ways that this level of interest in shorting Immutep shares can be evaluated.
Immutep's "short interest ratio" (SIR) is the quantity of Immutep shares currently shorted divided by the average quantity of Immutep shares traded daily (recently around 5.9 million). Immutep's SIR currently stands at 0.02. In other words for every 100,000 Immutep shares traded daily on the market, roughly 20 shares are currently held short.
However Immutep's short interest can also be evaluated against the total number of Immutep shares, or, against the total number of tradable Immutep shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immutep's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Immutep shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Immutep shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immutep.
Find out more about how you can short Immutep stock.
We're not expecting Immutep to pay a dividend over the next 12 months.
Immutep's shares were split on a 1:10 basis on 6 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep's share price.
Over the last 12 months, Immutep's shares have ranged in value from as little as $0.91 up to $3.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immutep's is 1.3206. This would suggest that Immutep's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc. , INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.